Inherited disorders of blood coagulation

References

• Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI)—how does thrombin regulate fibrinolysis? Ann Med. 2006;38:378–88.
   PubMed Web of Science ®Google Scholar
• Lippi G, Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over. Semin Thromb Hemost. 2008;34:747–61.
   PubMed Web of Science ®Google Scholar
• Laterre PF, Wittebole X, Collienne C. Pharmacological inhibition of tissue factor. Semin Thromb Hemost. 2006; 32: 71–6.
   PubMed Web of Science ®Google Scholar
• World Federation of Hemophilia. What is a bleeding disorder? Available at: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=26&contentid=5&rptnam=bleeding (accessed 23 July 2010).
   Google Scholar
• Franchini M, Targher G, Lippi G. Prophylaxis in von Willebrand disease. Ann Hematol. 2007;86:699–704.
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Genetic testing for von Willebrand disease: the case against. J Thromb Haemost. 2010;8:6–12.
   PubMed Web of Science ®Google Scholar
• Franchini M, Mannucci PM. Von Willebrand factor: another janus-faced hemostasis protein. Semin Thromb Hemost. 2008;34:663–9.
   PubMed Web of Science ®Google Scholar
• Sadler JE, Budde U, Eikenboom JCJ, Favaloro EJ, Hill FGH, Holmberg L, . Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4: 2103–14.
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Laboratory identification of von Willebrand disease: technical and scientific perspectives. Semin Thromb Hemost. 2006;32:456–71.
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Towards a new paradigm for the identification and functional characterisation of von Willebrand disease. Semin Thromb Hemost. 2009;35:60–75.
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin? Semin Thromb Hemost. 2008;34:113–27.
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Mohammed S, Koutts J. Identification and prevalence of von Willebrand Disease type 2N (Normandy) in Australia. Blood Coag Fibrinolysis. 2009;20:706–14.
   PubMed Web of Science ®Google Scholar
• Federici AB, Mannucci PM. Management of inherited von Willebrand disease in 2007. Ann Med. 2007;39:346–58.
   PubMed Web of Science ®Google Scholar
• Turecek PL, Schrenk G, Rottensteiner H, Varadi K, Bevers E, Lenting P, . Structure and function of a recombinant von Willebrand factor (VWF) drug candidate. Semin Thromb Hemost. 2010;36:510–21.
   PubMed Web of Science ®Google Scholar
• Bolton-Maggs PH, Pasi KJ. Haemophilia A and B. Lancet. 2003;361:1801–9.
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Tuddenham EG. The hemophilias—from royal genes to gene therapy. N Engl J Med. 2001;344: 1773–9.
   PubMed Web of Science ®Google Scholar
• Broze GJ, Higuchi D. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood. 1996;88: 3815–23.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Schwaab R. Molecular biology of blood coagulation. Semin Thromb Hemost. 2001;27:313–24.
   PubMed Web of Science ®Google Scholar
• White GC II, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia: recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85:560.
   PubMed Web of Science ®Google Scholar
• Franchini M, Coppola A, Molinari AC, Santoro C, Schinco P, Speciale V, . Forum on: the role of recombinant factor VIII in children with severe haemophilia A. Haemophilia. 2009;15:578–86.
   PubMed Web of Science ®Google Scholar
• Franchini M, Lippi G. Recombinant factor VIII concentrates. Semin Thromb Hemost. 2010;36:493–7.
   PubMed Web of Science ®Google Scholar
• Monahan PE, Di Paola J. Recombinant factor IX for clinical and research use. Semin Thromb Hemost. 2010;36:498–509.
   PubMed Web of Science ®Google Scholar
• Coppola A, Franchini M, Tagliaferri A. Prophylaxis in people with hemophilia. Thromb Haemost. 2009;101:674–81.
   PubMed Web of Science ®Google Scholar
• Tagliaferri A, Rivolta GF, Iorio A, Oliovecchio E, Mancuso ME, Morfini M, . for the Italian Association of Hemophilia Centers. Mortality and causes of death in Italian persons with haemophilia, 1990–2007. Haemophilia. 2010;16:437–46.
   PubMed Web of Science ®Google Scholar
• Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia. 2008;14 (Suppl 3): 10–18.
   PubMedGoogle Scholar
• Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J, . Possible transmission of variant Creutzfeldt–Jakob disease by blood transfusion. Lancet. 2004;363: 417–21.
   PubMed Web of Science ®Google Scholar
• Pipe SW. Recombinant clotting factors. Thromb Haemost. 2008;99:840–50.
   PubMed Web of Science ®Google Scholar
• Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood. 2003;102:2358–63.
   PubMed Web of Science ®Google Scholar
• Gouw SC, van den Berg HM. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Hemost. 2009;35:723–34.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Schröder J, Brackmann HH, Müller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development. Semin Hematol. 2004;41(Suppl 1):82–8.
   PubMed Web of Science ®Google Scholar
• Santagostino E, Mancuso ME, Rocino A, Mancuso G, Mazzucconi MG, Tagliaferri A, . Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol. 2005;130:422–7.
   PubMed Web of Science ®Google Scholar
• Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgård U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood. 2007;109:4693–7.
   PubMed Web of Science ®Google Scholar
• Goudemand J, Rothschild C, Demiguel V, Vinciguerrat C, Lambert T, Chambost H, . FVIII-LFB and Recombinant FVIII study groups. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood. 2006;107:46–51.
   PubMed Web of Science ®Google Scholar
• Chalmers EA, Brown SA, Keeling D, Liesner R, Richards M, Stirling D, . Paediatric Working Party of UKHCDO. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia. 2007;13:149–55.
   PubMed Web of Science ®Google Scholar
• Berntorp E, Shapiro A, Astermark J, Blanchette VS, Collins PW, Dimichele D, . Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia. 2006;12 (Suppl 6):1–7.
   PubMedGoogle Scholar
• Jadhav M, Warrier I. Anaphylaxis in patients with hemophilia. Semin Thromb Hemost. 2000;26:205–8.
   PubMed Web of Science ®Google Scholar
• Franchini M, Lippi G, Montagnana M, Targher G, Zaffanello M, Salvagno GL, . Anaphylaxis in patients with congenital bleeding disorders and inhibitors. Blood Coagul Fibrinolysis. 2009;20:225–9.
   PubMed Web of Science ®Google Scholar
• Verbruggen B, van Heerde WL, Laros-van Gorkom BA. Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen. Semin Thromb Hemost. 2009;35: 752–9.
   PubMed Web of Science ®Google Scholar
• Kershaw G, Jayakodi D, Dunkley S. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia center. Semin Thromb Hemost. 2009;35:760–8.
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Bonar R, Kershaw G, Duncan E, Sioufi J, Marsden K. Investigations from external quality assurance programs reveal a high degree of variation in the laboratory identification of coagulation factor inhibitors. Semin Thromb Hemost. 2009;35:794–805.
   PubMed Web of Science ®Google Scholar
• Franchini M, Lippi G. Recent improvements in the clinical treatment of coagulation factor inhibitors. Semin Thromb Hemost. 2009;35:806–13.
   PubMed Web of Science ®Google Scholar
• Mathews V, Nair SC, David S, Viswabandya A, Srivastava A. Management of hemophilia in patients with inhibitors: the perspective from developing countries. Semin Thromb Hemost. 2009;35:820–6.
   PubMed Web of Science ®Google Scholar
• Astermark J. Treatment of the bleeding inhibitor patient. Semin Thromb Hemost. 2003;29:77–85.
   PubMed Web of Science ®Google Scholar
• Von Depka M. Managing acute bleeds in the patient with haemopilia and inhibitors: options, efficacy and safety. Haemophilia. 2005;11(Suppl 1):18–23.
   PubMedGoogle Scholar
• Franchini M, Manzato F, Salvagno GL, Montagnana M, Zaffanello M, Lippi G. Prophylaxis in congenital hemophilia with inhibitors: the role of recombinant activated factor VII. Semin Thromb Hemost. 2009;35:814–9.
   PubMed Web of Science ®Google Scholar
• Ananyeva NM, Lee TK, Jain N, Shima M, Saenko EL. Inhibitors in hemophilia A: advances in elucidation of inhibitory mechanisms and in inhibitor management with bypassing agents. Semin Thromb Hemost. 2009;35:735–51.
   PubMed Web of Science ®Google Scholar
• DiMichele D, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia. 2007;13(Suppl 1):1–22.
   PubMedGoogle Scholar
• Viala NO, Larsen SR, Rasko JE. Gene therapy for hemophilia: clinical trials and technical tribulations. Semin Thromb Hemost. 2009;35:81–92.
   PubMed Web of Science ®Google Scholar
• Lippi G, Franchini M, Saenko EL. Gene therapy for hemophilia A. Friend or foe? Blood Coagul Fibrinolysis. 2009;20: 395–9.
   PubMed Web of Science ®Google Scholar
• World Federation of Hemophilia. What are rare clotting factor deficiencies? World Federation of Hemophilia; 2009.
   Google Scholar
• Peyvandi F, Palla R, Menegatti M, Mannucci PM. Introduction. Rare bleeding disorders: general aspects of clinical features, diagnosis, and management. Semin Thromb Hemost. 2009;35:349–55.
   PubMed Web of Science ®Google Scholar
• World Federation of Hemophilia. WFH report on the Annual Global Survey 2007. Available at: http://www.wfh.org/2/docs/Publications/Statistics/2007-Survey-Report.pdf (accessed 23 July 2010).
   Google Scholar
• de Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders. Semin Thromb Hemost. 2009;35:356–66.
   PubMed Web of Science ®Google Scholar
• de Moerloose P, Boehlen F, Neerman-Arbez M. Fibrinogen and the risk of thrombosis. Semin Thromb Hemost. 2010;36: 7–17.
   PubMed Web of Science ®Google Scholar
• Bolton-Maggs PHB, Perry DJ, Chalmers EA, Parapia LA, Wilde JT, Williams MD, . The rare coagulation disorders—review with guidelines for management from the United Kingdom Haemophilia Centre Doctors’ Organisation. Haemophilia. 2004;10:593–628.
   PubMed Web of Science ®Google Scholar
• Lancellotti S, De Cristofaro R. Congenital prothrombin deficiency. Semin Thromb Hemost. 2009;35:367–81.
   PubMed Web of Science ®Google Scholar
• Asselta R, Peyvandi F. Factor V deficiency. Semin Thromb Hemost. 2009;35:382–9.
   PubMedGoogle Scholar
• Spreafico M, Peyvandi F. Combined factor V and factor VIII deficiency. Semin Thromb Hemost. 2009;35:390–9.
   PubMed Web of Science ®Google Scholar
• Mariani G, Bernardi F. Factor VII deficiency. Semin Thromb Hemost. 2009;35:400–6.
   PubMed Web of Science ®Google Scholar
• Mariani G, Herrmann FH, Dolce A, Batorova A, Etro D, Peyvandi F, . International Factor VII Deficiency Study Group. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost. 2005; 93:481–7.
   PubMed Web of Science ®Google Scholar
• Lapecorella M, Mariani G; International Registry on Congenital Factor VII Deficiency. Factor VII deficiency: defining the clinical picture and optimizing therapeutic options. Haemophilia. 2008;14:1170–5.
   PubMed Web of Science ®Google Scholar
• Girolami A, Scandellari R, Lombardi AM. The use of tissue thromboplastins of different origin is a fundamental tool in the initial characterization of FVII defects on ‘factor VII deficiency (Semin Thromb Hemost 2009;35(4):400–406)’. Semin Thromb Hemost. 2010;36:123–4; author reply 125–7.
   PubMed Web of Science ®Google Scholar
• Brenner B, Kuperman AA, Watzka M, Oldenburg J. Vitamin K-dependent coagulation factors deficiency. Semin Thromb Hemost. 2009;35:439–46.
   PubMed Web of Science ®Google Scholar
• Wada H, Usui M, Sakuragawa N. Hemostatic abnormalities and liver diseases. Semin Thromb Hemost. 2008;34:772–8.
   PubMed Web of Science ®Google Scholar
• Menegatti M, Peyvandi F. Factor X deficiency. Semin Thromb Hemost. 2009;35:407–15.
   PubMed Web of Science ®Google Scholar
• Duga S, Salomon O. Factor XI deficiency. Semin Thromb Hemost. 2009;35:416–25.
   PubMedGoogle Scholar
• Stavrou E, Schmaier AH. Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis. Thromb Res. 2010;125:210–5.
   PubMed Web of Science ®Google Scholar
• Lippi G, Franchini M, Brazzarola P, Manzato F. Preoperative screening: the rationale of measuring APTT in risk assessment. Haematologica. 2001;86:328.
   PubMed Web of Science ®Google Scholar
• Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII deficiency. Semin Thromb Hemost. 2009;35:426–38.
   PubMed Web of Science ®Google Scholar